“A comprehensive diagnostic offering workflow increases the rate of actionable results of the 23- and 35-gene expression profile tests for use as ancillary diagnostic tools for difficult-to-diagnose melanocytic lesions”, J of Skin, vol. 5, no. 6, p. s79, Nov. 2021, doi: 10.25251/skin.5.supp.79.